WO2023286617A1 - ポリオキシエチレン誘導体に含まれる反応性低分子化合物の分析方法 - Google Patents
ポリオキシエチレン誘導体に含まれる反応性低分子化合物の分析方法 Download PDFInfo
- Publication number
- WO2023286617A1 WO2023286617A1 PCT/JP2022/026213 JP2022026213W WO2023286617A1 WO 2023286617 A1 WO2023286617 A1 WO 2023286617A1 JP 2022026213 W JP2022026213 W JP 2022026213W WO 2023286617 A1 WO2023286617 A1 WO 2023286617A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- group
- bond
- polyoxyethylene derivative
- Prior art date
Links
- -1 polyoxyethylene Polymers 0.000 title claims abstract description 42
- 229920003171 Poly (ethylene oxide) Polymers 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title description 7
- 150000003384 small molecules Chemical class 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 50
- 238000004458 analytical method Methods 0.000 claims abstract description 39
- 239000000126 substance Substances 0.000 claims abstract description 22
- 239000000654 additive Substances 0.000 claims abstract description 11
- 230000000996 additive effect Effects 0.000 claims abstract description 10
- 230000008033 biological extinction Effects 0.000 claims abstract description 10
- 230000002378 acidificating effect Effects 0.000 claims abstract description 9
- 238000001514 detection method Methods 0.000 claims abstract description 7
- 238000004366 reverse phase liquid chromatography Methods 0.000 claims abstract description 7
- 125000002947 alkylene group Chemical group 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 239000004202 carbamide Substances 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 239000000523 sample Substances 0.000 description 16
- 239000003480 eluent Substances 0.000 description 13
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 239000012488 sample solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- 239000000538 analytical sample Substances 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 1
- BYACHAOCSIPLCM-UHFFFAOYSA-N 2-[2-[bis(2-hydroxyethyl)amino]ethyl-(2-hydroxyethyl)amino]ethanol Chemical compound OCCN(CCO)CCN(CCO)CCO BYACHAOCSIPLCM-UHFFFAOYSA-N 0.000 description 1
- TXBCBTDQIULDIA-UHFFFAOYSA-N 2-[[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]methyl]-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC(CO)(CO)CO TXBCBTDQIULDIA-UHFFFAOYSA-N 0.000 description 1
- PTJWCLYPVFJWMP-UHFFFAOYSA-N 2-[[3-hydroxy-2-[[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]methyl]-2-(hydroxymethyl)propoxy]methyl]-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC(CO)(CO)COCC(CO)(CO)CO PTJWCLYPVFJWMP-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 241001662443 Phemeranthus parviflorus Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 125000004036 acetal group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical group 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 229920001002 functional polymer Polymers 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 125000001802 myricyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
- B01J20/286—Phases chemically bonded to a substrate, e.g. to silica or to polymers
- B01J20/287—Non-polar phases; Reversed phases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/74—Optical detectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
Definitions
- the compound of formula (1) has an N-succinimidyloxycarbonylamino group and an N-succinimidyloxycarbonyl group at both ends, and these functional groups are reactive with amino groups. Therefore, application as a bifunctional linker has also been proposed (Patent Document 1, Non-Patent Document 3).
- Patent Document 1 Non-Patent Document 3
- the compound of formula (1) when the compound of formula (1) is contained in the polyoxyethylene derivative, the compound of formula (1) also reacts with the bio-related substance like the polyoxyethylene derivative when chemically modifying the bio-related substance such as protein. It causes impurities in the drug product. Therefore, highly sensitive analysis is required in order to control the content of the compound of formula (1) contained in a small amount in the polyoxyethylene derivative.
- Methods for detecting low-molecular-weight compounds with high sensitivity generally include ultraviolet-visible spectroscopic detectors, fluorescence detectors, mass spectrometry detectors, and the like.
- the compound of formula (1) cannot be detected because the fluorescence detector can only detect compounds that exhibit fluorescence.
- mass spectrometry detectors are very expensive and have many limitations such as the inability to use non-volatile eluents and contamination of the detector when measuring high-concentration samples.
- UV-visible spectroscopic detectors are inexpensive, can be used with many eluents regardless of whether they are volatile or non-volatile, and do not contaminate the detector with high-concentration samples, making them highly versatile detectors. It is widely used, and it is preferable to use an ultraviolet-visible spectroscopic detector as a detector also in the analysis method of the present invention.
- the wavelength used for detection ultraviolet rays with a wavelength shorter than 200 nm are used, but ultraviolet rays with a wavelength of 190 to 200 nm are preferably used, and ultraviolet rays with a wavelength of 194 nm are particularly preferably used.
- the separation mode used in the analysis method of the present invention is preferably reversed-phase chromatography, and silica-based particles modified with an octadecyl group (C18), an octyl group (C8), a phenyl group (Ph), a triacontyl group (C30) or similarly modified More preferred is reversed-phase chromatography using a column packed with polymer-based particles modified with modified polymer bases, and particularly preferred is reversed-phase chromatography using a column packed with silica-based particles modified with octadecyl groups.
- a stainless steel column having a column length of 5 to 25 cm and an inner diameter of 1 to 6 mm can be used for the analysis, and a column having a length of 15 to 25 cm and an inner diameter of 2 to 5 mm is preferable.
- the particle size of the filler is preferably 2-10 ⁇ m, particularly preferably 2-5 ⁇ m.
- the filler is preferably a wholly porous particle or a superficially porous particle, and preferably has a pore size of 5 to 50 nm, particularly preferably 7 to 30 nm.
- the column temperature is preferably 5 to 60°C, particularly preferably 20 to 40°C.
- a mixture of water and an organic solvent can be used as an eluent (mobile phase for analysis) used for analysis.
- organic solvent polar solvents miscible with water such as acetonitrile, methanol, and 2-propanol can be used, and acetonitrile is preferably used.
- the mixing ratio of the organic solvent can be in the range of 10 to 80% by volume, preferably in the range of 20 to 50%.
- the water and the organic solvent can be premixed or continuously mixed by gradient analysis, with premixed eluents being particularly preferred. Since the compound of formula (1) is known to react with water under neutral to basic conditions and decompose, the eluent must be under acidic conditions. Additives can be added to the eluent, preferably 0.01 to 1% of an acidic substance or a salt thereof.
- the acidic substance to be added has a large molar extinction coefficient in ultraviolet light with a wavelength of 190 to 200 nm
- the baseline of the chromatogram and the peak of the compound of formula (1) may overlap, resulting in a decrease in peak detection sensitivity and analytical reproducibility. cause a decrease in
- the pKa is preferably 4 or less.
- the acidic substance to be added is preferably an acidic substance having a maximum molar extinction coefficient of 20 M ⁇ 1 cm ⁇ 1 or less and a pKa of 4 or less in ultraviolet rays with a wavelength of 190 to 200 nm, and a maximum molar extinction coefficient of 5 M ⁇ 1 cm ⁇ 1 or less and pKa. is 3 or less, more preferably phosphoric acid or perchloric acid, and most preferably phosphoric acid.
- the eluent feeding rate is preferably 0.1 to 4 mL/min, particularly preferably 0.2 to 1.5 mL/min.
- the analytical sample of the present invention is a polyoxyethylene derivative containing the compound of formula (1).
- the polyoxyethylene derivative is dissolved using an aprotic organic solvent, and the eluent used for analysis is It is preferable to dissolve using a solvent miscible with.
- a solvent miscible with In general, in liquid chromatography, when the eluent and the dissolution liquid of the analysis sample are different, ghost peaks may appear that interfere with the analysis. Therefore, it is preferable to use the organic solvent used for the eluent.
- an acidic substance can be added as an additive to the solution of the analytical sample. is preferably used, and it is particularly preferable to use trifluoroacetic acid.
- the concentration of the polyoxyethylene derivative is preferably 50-300 mg/mL, particularly preferably 50-200 mg/mL.
- the sample injection amount (volume) at the time of analysis is preferably 0.2% or more and 0.5% or less, particularly preferably 0.2% or more and 0.3% or less, of the column volume.
- the sample concentration used for analysis is C (mg/mL)
- the sample injection volume is I (mL)
- the column volume is V (mL)
- the sample volume per column volume is expressed as "C ⁇ I ⁇ V”.
- C ⁇ I ⁇ V is preferably 0.1 or more and 1.5 or less, and particularly preferably 0.1 or more and 0.6 or less.
- a and b are the average number of added moles of oxyethylene groups, each being 0 to 5000, preferably 0 to 1000, and a+b being 20 or more.
- Compounds having 2 to 8 hydroxyl groups in the definition of Z in formula (2) and having 2 to 21 carbon atoms and optionally containing oxygen and/or nitrogen atoms include, for example, ethylene glycol and triethanol.
- the alkoxy group in the definition of X 1 in formula (2) includes, for example, a linear or branched alkoxyl group having 1 to 6 carbon atoms, such as a methoxy group, an ethoxy group, a propoxy group or an isopropyloxy group.
- a methoxy group is preferred, and a methoxy group is more preferred.
- X2 is an N - succinimidyloxycarbonyl group.
- Z in formula (2) is a glycerin residue.
- Z in formula (2) is a xylitol residue.
- Z in formula (2) is a pentaerythritol residue.
- Z in formula (2) is a hexaglycerin residue.
- L 1 and L 2 in formula (2) are each independently a divalent spacer, and these spacers are not particularly limited as long as they are groups capable of forming a covalent bond, but preferably ester A bond, an amide bond, an ether bond, a thioether bond, a urethane bond, a urea bond, or an alkylene group that may contain these bonds, more preferably an ester bond, an amide bond, an ether bond, a urethane bond, or these is an alkylene group which may contain a bond, and particularly preferred embodiments are those shown in the following group (I). Two to five spacers of group (I) may be combined.
- L 1 in formula (2) is (z1), (z2), (z3), (z4), (z5), (z6), (z7), (z8), (z9) of group (I) , (z10) are preferred, and (z1), (z2), (z6) and (z9) are more preferred.
- L 2 in formula (2) is (z2), (z3), (z4), (z5), (z6), (z7), (z8), (z9), (z10) of group (I) are preferred, and (z2), (z6) and (z9) are more preferred.
- p in formula (2) is preferably 0.
- the present invention is not limited to the configurations described in the above embodiments, and includes, for example, the following configurations.
- the skeleton of the compound of formula (4) may be the skeleton of formula (11) below
- the skeleton of the compound of formula (5) may be the skeleton of formula (12) below.
- the compound of formula (11) and the compound of formula (12) can also exhibit the same effect as the above embodiment.
- Example 1 10.0 mg of the compound of formula (1) ( ⁇ -Ala-NHS) was weighed into a 50 mL volumetric flask, dissolved in acetonitrile, and then diluted to 0.2 mg/mL. 0.5 mL of this solution was accurately weighed into a 100 mL volumetric flask and filled up with an acetonitrile solution containing 0.1% TFA to prepare an additive solution (0.001 mg/mL). Next, the compound of formula (8) (manufactured by NOF, SUNBRIGHT ME-200HS) is added to a 1 mL volumetric flask.
- Example 1 100 mg of was weighed out, and 0.5 mL of the additive solution was accurately weighed and added thereto, and then diluted with 0.1% TFA-containing acetonitrile to prepare an analysis sample solution (100 mg / mL, for the compound of formula (8) ⁇ -Ala-NHS was added at 5 ppm).
- the analysis sample solution was subjected to HPLC measurement under the following conditions. The peak height of ⁇ -Ala-NHS in the analysis sample at this time was 2325 and the S/N ratio was 56.
- HPLC apparatus Alliance 2695 (Nippon Waters Co., Ltd.)
- Flow rate 1.0 mL/min
- Analysis time 20 minutes
- Column temperature: 40°C Eluent: water/acetonitrile 7/3, containing 0.02% phosphoric acid
- Detector UV-visible spectroscopic detector (194 nm) (Nippon Waters Co., Ltd.)
- Example 2 When preparing the analysis sample solution, the compound of formula (8) to be weighed is changed from 100 mg to 30 mg, and the amount of the added solution is changed from 0.5 mL to 0.15 mL. 5 ppm of ⁇ -Ala-NHS added to the compound of formula (8)) to 30 mg/mL (5 ppm of ⁇ -Ala-NHS added to the compound of formula (8)) under the same conditions as in Example 1. HPLC measurements were performed at The peak height of ⁇ -Ala-NHS in the analytical sample at this time was 698 and the S/N ratio was 11.
- sample concentration C (mg / mL) in Example 2 is 30 mg / mL
- sample injection volume I (mL) is 0.01 mL
- the present invention provides a highly sensitive analytical method for low-molecular-weight compounds contained in polyoxyethylene derivatives.
Landscapes
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
以上のように、末端にN-スクシンイミジルオキシカルボニル基を有するポリオキシエチレン誘導体の合成時に副生する式(1)の化合物は、少量であっても生体関連物質と反応し不純物副生の原因となることから、医薬品の品質管理の観点において、ポリオキシエチレン誘導体に含まれる式(1)の化合物を高感度に分析することが求められる。
(1) ポリオキシエチレン誘導体に含まれる式(1)
低分子化合物を高感度に検出する方法としては、一般的に紫外可視分光検出器、蛍光検出器、質量分析検出器などが挙げられる。しかしながら蛍光検出器は蛍光を示す化合物でなければ検出できないことから式(1)の化合物は検出できない。また質量分析検出器は非常に高価であり、不揮発性の溶離液を使用できない、高濃度サンプルを測定すると検出器が汚染されるなどの制限も多い。一方で紫外可視分光検出器は安価であり、揮発性・不揮発性に関わらず多くの溶離液を使用可能であり、高濃度サンプルによる検出器の汚染もないことから、汎用性の高い検出器として広く普及しており、本発明の分析方法においても検出器は紫外可視分光検出器を用いることが好ましい。検出に用いる波長(検出波長)としては、200nmより短波長の紫外線を用いるが、190~200nmの紫外線を用いることが好ましく、194nmの紫外線を用いることが特に好ましい。
本発明は、上記実施形態で説明した構成に限らず、例えば、以下の構成も本発明に含まれる。
例えば、式(4)の化合物の骨格を以下の式(11)の骨格としてもよいし、式(5)の化合物の骨格を以下の式(12)の骨格としてもよい。これら式(11)の化合物及び式(12)の化合物においても上記実施形態と同様の効果を奏し得る。
50mLメスフラスコに式(1)の化合物(β-Ala-NHS)を10.0mgはかり取り、これをアセトニトリルで溶解後メスアップした(0.2mg/mL)。この溶液を100mLメスフラスコに0.5mLを正確にはかりとり、0.1%TFA含有アセトニトリル溶液でメスアップし、添加溶液を調製した(0.001mg/mL)。次に、1mLメスフラスコに式(8)の化合物(日油製、SUNBRIGHT ME-200HS)
なお、実施例1における試料濃度 C (mg/mL)は100mg/mL、試料注入量 I (mL)は0.01mL、カラム体積 V (mL)は4.15mLであることからC×I÷V=100×0.01÷4.15=0.24である。
HPLC装置: Alliance2695 (日本ウォーターズ株式会社)
カラム: Inetsil ODS-3 (内径4.6mm、長さ250mm、粒子径5μm)
流速: 1.0mL/分
分析時間: 20分
カラム温度: 40℃
溶離液: 水/アセトニトリル=7/3、0.02%リン酸含有
注入量: 10μL
検出器: 紫外可視分光検出器(194nm)(日本ウォーターズ株式会社)
実施例1の分析試料溶液を用い、HPLCの溶離液の添加剤を0.02%リン酸(190~200nmの最大モル吸光係数ε=1.2M-1cm-1, pKa=2.1)から0.1%酢酸(190~200nmの最大モル吸光係数ε=38M-1cm-1, pKa=4.8)へ変更し、添加剤以外は全て実施例1と同一の条件でHPLC測定を行った。この時の分析試料溶液におけるβ-Ala-NHSのピーク高さは769、S/N比は2であった。
実施例1の分析試料溶液を用い、HPLCの溶離液の添加剤を0.02%りん酸(190~200nmの最大モル吸光係数ε=1.2M-1cm-1, pKa=2.1)から0.1%TFA(190~200nmの最大モル吸光係数ε=216M-1cm-1, pKa=0.5)へ変更し、添加剤以外は全て実施例1と同一の条件でHPLC測定を行った。この時の分析試料溶液におけるβ-Ala-NHSのピーク高さは540、S/N比は2であった。
分析試料溶液の調製時にはかりとる式(8)の化合物を100mgから30mgへ変更し、添加溶液の量を0.5mLから0.15mLへ変更することで調製する試料濃度を100mg/mL(式(8)の化合物に対してβ-Ala-NHSを5ppm添加)から30mg/mL(式(8)の化合物に対してβ-Ala-NHSを5ppm添加)へ変更し、実施例1と同一の条件でHPLC測定を行った。この時の分析試料におけるβ-Ala-NHSのピーク高さは698、S/N比は11であった。
なお、実施例2における試料濃度 C (mg/mL)は30mg/mL、試料注入量 I (mL)は0.01mL、カラム体積 V (mL)は4.15mLであることからC×I÷V=30×0.01÷4.15=0.07である。
実施例1の化合物(8)から式(9)の化合物
実施例1の化合物(8)から式(10)の化合物
Claims (2)
- ポリオキシエチレン誘導体が式(2)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023535234A JPWO2023286617A1 (ja) | 2021-07-13 | 2022-06-30 | |
EP22841961.0A EP4371662A1 (en) | 2021-07-13 | 2022-06-30 | Method for analyzing reactive low-molecular-weight compound contained in polyoxyethylene derivative |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021-115693 | 2021-07-13 | ||
JP2021115693 | 2021-07-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023286617A1 true WO2023286617A1 (ja) | 2023-01-19 |
Family
ID=84920076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/026213 WO2023286617A1 (ja) | 2021-07-13 | 2022-06-30 | ポリオキシエチレン誘導体に含まれる反応性低分子化合物の分析方法 |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4371662A1 (ja) |
JP (1) | JPWO2023286617A1 (ja) |
WO (1) | WO2023286617A1 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005208050A (ja) * | 2003-12-26 | 2005-08-04 | Nof Corp | ポリオキシアルキレン誘導体の末端活性化率分析方法 |
WO2010107520A1 (en) * | 2009-03-20 | 2010-09-23 | Smartcells, Inc. | Soluble non-depot insulin conjugates and uses thereof |
JP2018172649A (ja) * | 2017-03-31 | 2018-11-08 | 日油株式会社 | 末端に複数の水酸基を有するポリオキシエチレン誘導体の製造方法 |
JP2021115693A (ja) | 2020-01-23 | 2021-08-10 | オムロン株式会社 | ロボットシステムの制御装置、ロボットシステムの制御方法、コンピュータ制御プログラム、及びロボットシステム |
-
2022
- 2022-06-30 JP JP2023535234A patent/JPWO2023286617A1/ja active Pending
- 2022-06-30 EP EP22841961.0A patent/EP4371662A1/en active Pending
- 2022-06-30 WO PCT/JP2022/026213 patent/WO2023286617A1/ja active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005208050A (ja) * | 2003-12-26 | 2005-08-04 | Nof Corp | ポリオキシアルキレン誘導体の末端活性化率分析方法 |
WO2010107520A1 (en) * | 2009-03-20 | 2010-09-23 | Smartcells, Inc. | Soluble non-depot insulin conjugates and uses thereof |
JP2018172649A (ja) * | 2017-03-31 | 2018-11-08 | 日油株式会社 | 末端に複数の水酸基を有するポリオキシエチレン誘導体の製造方法 |
JP2021115693A (ja) | 2020-01-23 | 2021-08-10 | オムロン株式会社 | ロボットシステムの制御装置、ロボットシステムの制御方法、コンピュータ制御プログラム、及びロボットシステム |
Non-Patent Citations (4)
Title |
---|
GROSS H., BILK L.: "Zur reaktion von N-Hydroxysuccinimid mit dicyclohexylcarbodiimid", TETRAHEDRON, ELSEVIER SIENCE PUBLISHERS, AMSTERDAM, NL, vol. 24, no. 24, 1 January 1968 (1968-01-01), AMSTERDAM, NL , pages 6935 - 6939, XP093023922, ISSN: 0040-4020, DOI: 10.1016/S0040-4020(01)96807-3 * |
REACTIVE FUNCTIONAL POLYMERS, vol. 67, 2007, pages 529 - 539 |
TETRAHEDRON, vol. 24, no. 21994-89-8, 1968, pages 6935 - 6939 |
WILCHEK MEIR, MIRON TALIA: "Limitations of A-Hydroxysuccinimide Esters in Affinity Chromatography and Protein Immobilization1'", BIOCHEMISTRY, vol. 26, no. 141, 1 January 1987 (1987-01-01), pages 2155 - 2161, XP093023921, ISSN: 0006-2960 * |
Also Published As
Publication number | Publication date |
---|---|
EP4371662A1 (en) | 2024-05-22 |
JPWO2023286617A1 (ja) | 2023-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Padró et al. | State-of-the-art and recent developments of immobilized polysaccharide-based chiral stationary phases for enantioseparations by high-performance liquid chromatography (2013–2017) | |
CN110146631B (zh) | 一种药用材料中聚乙二醇单甲醚残留量的检测方法 | |
EP3318591B1 (en) | Hetero type monodispersed polyethylene glycol, intermediate for production of hetero type monodispersed polyethylene glycol, methods for producing same, and hetero type monodispersed polyethylene glycol conjugate | |
CN111855881B (zh) | 一种阿齐沙坦中盐酸羟胺的检测方法 | |
KR20070112149A (ko) | 활성화 폴리에틸렌 글리콜 화합물의 분석방법 | |
WO2023286617A1 (ja) | ポリオキシエチレン誘導体に含まれる反応性低分子化合物の分析方法 | |
Allenmark et al. | N-(9-acridinyl)-bromoacetamide—A powerful reagent for phase-transfer-catalyzed fluorescence labeling of carboxylic acids for liquid chromatography | |
Fraier et al. | A sensitive procedure for the quantitation of free and N-(2-hydroxypropyl) methacrylamide polymer-bound doxorubicin (PK1) and some of its metabolites, 13-dihydrodoxorubicin, 13-dihydrodoxorubicinone and doxorubicinone, in human plasma and urine by reversed-phase HPLC with fluorimetric detection | |
RU2416792C1 (ru) | Способ количественного определения ципрофлоксацина в лекарственных препаратах | |
Husain et al. | High-performance liquid chromatographic separation and determination of small amounts of process impurities of ciprofloxacin in bulk drugs and formulations | |
CN113125583A (zh) | 一种注射用泮托拉唑钠中基因毒性杂质含量的检测方法 | |
Reddy et al. | Rapid and sensitive HPLC method for the estimation of doxorubicin in dog blood-the silver nitrate artifact | |
Brendel et al. | Simultaneous determination of 5-aminosalicylic acid and 5-acetylaminosalicylic acid by high-performance liquid chromatography | |
CN114280191B (zh) | 一种双半胱氨酸及其制剂中有关物质的检测方法 | |
CN107525875B (zh) | 一种加米霉素有关物质的检测方法 | |
Kudoh et al. | Determination of tertiary aliphatic amines by high-performance liquid chromatography | |
CN111624276B (zh) | 同时检测盐酸法舒地尔中基因毒性杂质5-异喹啉磺酸甲酯和5-异喹啉磺酸乙酯的方法 | |
CN113640403A (zh) | 甲磺酸帕珠沙星原料药的含量检测方法 | |
CN110261496B (zh) | 一种四氢姜黄素的含量检测方法 | |
JP4543917B2 (ja) | ポリオキシアルキレン誘導体の末端活性化率分析方法 | |
CN114839293B (zh) | 一种羟苯磺酸钙中遗传毒性杂质的定量测定方法 | |
CN114280190B (zh) | 一种用于检测双半胱氨酸有关物质的试剂盒 | |
CN114137133B (zh) | 一种纳洛醇-peg衍生物有关物质的检测方法 | |
CN116930365A (zh) | 一种单端epox修饰的peg产品的检测方法 | |
CN107202848B (zh) | 一种氯法齐明的液相色谱分析方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22841961 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023535234 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022841961 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022841961 Country of ref document: EP Effective date: 20240213 |